Status:

COMPLETED

The Effect of the Alga Dunaliella Bardawil as a Source of 9-cis Retinoic Acid on Lipid Profile in Fibrate Treated Patients.

Lead Sponsor:

Sheba Medical Center

Conditions:

Low HDL Cholesterol

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

The effect of fibrates on high density lipoprotein (HDL)-cholesterol levels is suggested to be mediated by its binding to peroxisome proliferator-activated receptor-g (PPARg). Upon ligand binding, PPA...

Eligibility Criteria

Inclusion

  • age 18-70 years
  • Fibrate treatment (for at least 6 weeks)
  • HDL-Cholesterol lower than 40mg/dl.
  • Triglyceride over 150mg/dl.

Exclusion

  • High CPK.
  • Elevated liver functions.
  • Active CHD.
  • Smokers.
  • Diabetes patients treated with Insulin or Avandia. HbA1C great than 8.5.

Key Trial Info

Start Date :

May 1 2001

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2006

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT00156169

Start Date

May 1 2001

End Date

December 1 2006

Last Update

August 12 2009

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.